The investment bank said it is encouraged by the company's strong pipeline and position among its competitors but sees further upside for its stock.
With NIPT samples from more than 141,000 women in China, investigators retraced population structure, historical migrations, genetic associations, and more.
The placing and subscription shares that are part of the offering are expected to start trading on the AIM market of the London Stock Exchange later this month.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.
A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
The firm recognized $63.1 million in revenues and processed 162,807 tests in the second quarter 2018.
A team of researchers in Japan used a noninvasive prenatal testing platform to detect copy number alterations in about 20 percent of gynecological cancers they tested.
The company is using its informatics services business to inform internal diagnostic research and development efforts.
The partners will test PerkinElmer's Vanadis NIPT platform on samples from 2,650 women to determine detection and false positive rates.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.
Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.
Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.